Standout Papers
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy (2010)
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies (2012)
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 (2011)
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo (2011)
Immediate Impact
8 by Nobel laureates 16 from Science/Nature 66 standout
Citing Papers
PROTACs: past, present and future
2022 Standout
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
2022 Standout
Works of Joseph J. Buggy being referenced
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
2011 Standout
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
2010 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Joseph J. Buggy | 4063 | 2845 | 3036 | 82 | 7.0k | |
| Betty Chang | 3479 | 4334 | 2723 | 76 | 9.2k | |
| Thorsten Zenz | 3466 | 2358 | 2512 | 164 | 6.3k | |
| Alan Saven | 2616 | 1424 | 1863 | 119 | 5.6k | |
| R. Eric Davis | 1870 | 3698 | 2387 | 160 | 8.2k | |
| Brian J. Lannutti | 2598 | 1800 | 1654 | 75 | 3.9k | |
| Marcel Spaargaren | 1196 | 3034 | 1264 | 97 | 5.7k | |
| Neill A. Giese | 1737 | 2203 | 909 | 43 | 4.5k | |
| Taghi Manshouri | 3113 | 2995 | 722 | 140 | 6.1k | |
| Enrique M. Ocio | 1345 | 2584 | 1121 | 199 | 5.0k | |
| Stanley R. Frankel | 924 | 5085 | 1184 | 72 | 7.9k |
All Works
Loading papers...